Cartesian Therapeutics (RNAC) Return on Capital Employed (2016 - 2026)

Cartesian Therapeutics (RNAC) has 11 years of Return on Capital Employed data on file, last reported at 53.54% in Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 4066.0% year-over-year to 53.54% in Q1 2026; TTM through Mar 2026 was 53.54%, a 4066.0% decrease from a year earlier, with the FY2025 full-year figure at 40.88%, down 2823.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 53.54%, down from 44.87% in the prior quarter.
• Over the last five years, Return on Capital Employed for RNAC reached as high as 20.09% in Q2 2022 and fell as low as 62.92% in Q4 2023.
• Historically, Return on Capital Employed has averaged 20.02% across 5 years, with a median of 15.78% in 2024.
• Across the five-year window, Return on Capital Employed soared 6396 bps in 2022 and sank 7397 bps in 2023, its largest moves.
• Year by year, Return on Capital Employed stood at 9.89% in 2022, then plunged by 736 bps to 62.92% in 2023, then surged by 83 bps to 10.4% in 2024, then plunged by 332 bps to 44.87% in 2025, then declined by 19 bps to 53.54% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 53.54% in Q1 2026, 44.87% in Q4 2025, and 24.93% in Q3 2025.